Literature DB >> 22345649

Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18.

Virginie Prod'homme1, Peter Tomasec, Charles Cunningham, Marius K Lemberg, Richard J Stanton, Brian P McSharry, Eddie C Y Wang, Simone Cuff, Bruno Martoglio, Andrew J Davison, Véronique M Braud, Gavin W G Wilkinson.   

Abstract

Human CMV (HCMV)-encoded NK cell-evasion functions include an MHC class I homolog (UL18) with high affinity for the leukocyte inhibitory receptor-1 (CD85j, ILT2, or LILRB1) and a signal peptide (SP(UL40)) that acts by upregulating cell surface expression of HLA-E. Detailed characterization of SP(UL40) revealed that the N-terminal 14 aa residues bestowed TAP-independent upregulation of HLA-E, whereas C region sequences delayed processing of SP(UL40) by a signal peptide peptidase-type intramembrane protease. Most significantly, the consensus HLA-E-binding epitope within SP(UL40) was shown to promote cell surface expression of both HLA-E and gpUL18. UL40 was found to possess two transcription start sites, with utilization of the downstream site resulting in translation being initiated within the HLA-E-binding epitope (P2). Remarkably, this truncated SP(UL40) was functional and retained the capacity to upregulate gpUL18 but not HLA-E. Thus, our findings identify an elegant mechanism by which an HCMV signal peptide differentially regulates two distinct NK cell-evasion pathways. Moreover, we describe a natural SP(UL40) mutant that provides a clear example of an HCMV clinical virus with a defect in an NK cell-evasion function and exemplifies issues that confront the virus when adapting to immunogenetic diversity in the host.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345649      PMCID: PMC3303119          DOI: 10.4049/jimmunol.1102068

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities.

Authors:  Roland K Strong; Margaret A Holmes; Pingwei Li; Laura Braun; Ni Lee; Daniel E Geraghty
Journal:  J Biol Chem       Date:  2002-10-30       Impact factor: 5.157

2.  Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor.

Authors:  Benjamin E Willcox; Leonard M Thomas; Pamela J Bjorkman
Journal:  Nat Immunol       Date:  2003-08-03       Impact factor: 25.606

3.  Genetic content of wild-type human cytomegalovirus.

Authors:  Aidan Dolan; Charles Cunningham; Ralph D Hector; Aycan F Hassan-Walker; Lydia Lee; Clare Addison; Derrick J Dargan; Duncan J McGeoch; Derek Gatherer; Vincent C Emery; Paul D Griffiths; Christian Sinzger; Brian P McSharry; Gavin W G Wilkinson; Andrew J Davison
Journal:  J Gen Virol       Date:  2004-05       Impact factor: 3.891

4.  NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.

Authors:  Giuliana Magri; Aura Muntasell; Neus Romo; Andrea Sáez-Borderías; Daniela Pende; Daniel E Geraghty; Hartmut Hengel; Ana Angulo; Alessandro Moretta; Miguel López-Botet
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

5.  Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics.

Authors:  Brett K Kaiser; Fariba Barahmand-Pour; Wendy Paulsene; Scott Medley; Daniel E Geraghty; Roland K Strong
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

6.  Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus.

Authors:  Scott G Hansen; Colin J Powers; Rebecca Richards; Abigail B Ventura; Julia C Ford; Don Siess; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Louis J Picker; Klaus Früh
Journal:  Science       Date:  2010-04-02       Impact factor: 47.728

7.  Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor.

Authors:  A Weihofen; M K Lemberg; H L Ploegh; M Bogyo; B Martoglio
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

8.  UL40 human cytomegalovirus variability evolution patterns over time in renal transplant recipients.

Authors:  Isabelle Garrigue; Muriel Faure-Della Corte; Noël Magnin; Patricia Recordon-Pinson; Lionel Couzi; Marie-Elise Lebrette; Marie-Hélène Schrive; Loïc Roncin; Jean-Luc Taupin; Julie Déchanet-Merville; Hervé Fleury; Marie-Edith Lafon
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

9.  Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homolog) gene deleted.

Authors:  H Browne; M Churcher; T Minson
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector.

Authors:  G W Wilkinson; A Akrigg
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

View more
  44 in total

Review 1.  Harnessing adaptive natural killer cells in cancer immunotherapy.

Authors:  Lisa L Liu; Aline Pfefferle; Vincent Oei Yi Sheng; Andreas T Björklund; Vivien Béziat; Jodie P Goodridge; Karl-Johan Malmberg
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

2.  High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination.

Authors:  Steven Sijmons; Kim Thys; Mirabeau Mbong Ngwese; Ellen Van Damme; Jan Dvorak; Marnix Van Loock; Guangdi Li; Ruth Tachezy; Laurent Busson; Jeroen Aerssens; Marc Van Ranst; Piet Maes
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 3.  Origins of natural killer cell memory: special creation or adaptive evolution.

Authors:  Kayla A Holder; Emilie M Comeau; Michael D Grant
Journal:  Immunology       Date:  2018-02-15       Impact factor: 7.397

4.  The AgrD N-terminal leader peptide of Staphylococcus aureus has cytolytic and amyloidogenic properties.

Authors:  Kelly Schwartz; Matthew D Sekedat; Adnan K Syed; Brendan O'Hara; David E Payne; Abigail Lamb; Blaise R Boles
Journal:  Infect Immun       Date:  2014-06-30       Impact factor: 3.441

5.  Bruton's agammaglobulinemia in an adult male due to a novel mutation: a case report.

Authors:  Yuanda Xu; Qi Qing; Xuesong Liu; Sibei Chen; Ziyi Chen; Xuefeng Niu; Yaxia Tan; Weiqun He; Xiaoqing Liu; Yimin Li; Rongchang Chen; Ling Chen
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 6.  Herpesvirus Evasion of Natural Killer Cells.

Authors:  Steffi De Pelsmaeker; Nicolas Romero; Massimo Vitale; Herman W Favoreel
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 7.  Roles of regulated intramembrane proteolysis in virus infection and antiviral immunity.

Authors:  Jin Ye
Journal:  Biochim Biophys Acta       Date:  2013-12

8.  Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells.

Authors:  Susan L Heatley; Gabriella Pietra; Jie Lin; Jacqueline M L Widjaja; Christopher M Harpur; Sue Lester; Jamie Rossjohn; Jeff Szer; Anthony Schwarer; Kenneth Bradstock; Peter G Bardy; Maria Cristina Mingari; Lorenzo Moretta; Lucy C Sullivan; Andrew G Brooks
Journal:  J Biol Chem       Date:  2013-01-18       Impact factor: 5.157

9.  Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.

Authors:  Luke R Williams; Laura L Quinn; Martin Rowe; Jianmin Zuo
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

10.  The genetic contribution of HLA-E*01:03 and HLA-E*01:03-G*01:01 to Posner-Schlossman syndrome in southern Chinese.

Authors:  Xiaosheng Huang; Yunping Xu; Wenchieh Chen; Tianhui Zhu; Liumei He; Songxing Wang; Shiming Peng; Shaoyi Mei; Yan Wang; Jun Zhao
Journal:  Ann Transl Med       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.